Eder Therapeutics creates a patient‑centric healthcare ecosystem for Canadians with rare diseases, linking patients to innovative therapies, education, and support services. By coordinating partnerships with research institutions, biotech firms, and market‑access experts, it accelerates drug development, regulatory approval, and reimbursement, while providing navigation assistance and real‑world evidence to improve treatment availability and outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with rare diseases in Canada often face limited access to approved therapies, fragmented support services, and a lack of coordinated care among healthcare providers, payers, and patient organizations.
Solution
Eder Therapeutics builds a patient‑centric healthcare ecosystem that connects Canadian rare‑disease patients with innovative treatments, education, and support services. By leveraging partnerships with federal research agencies, clinical research organizations, market‑access consultants, and biotech innovators, the company accelerates the development, regulatory approval, and commercial launch of therapies that might otherwise remain unavailable. Eder provides coordinated disease‑management resources, including patient education, navigation assistance, and access programs, while facilitating data‑driven market‑access strategies and real‑world evidence generation to support reimbursement and payer negotiations. The integrated model aims to improve treatment availability, streamline care pathways, and enhance outcomes for diverse Canadian communities affected by rare diseases.
Target Audience
Primary customers are Canadian patients and families affected by rare diseases, as well as healthcare providers, payers, and non‑profit organizations seeking coordinated access to innovative therapies.
Features
- End‑to‑end partnership network spanning research institutions, clinical trial groups, and market‑access experts to fast‑track rare‑disease drug development and launch
- Patient‑focused services such as disease education, navigation assistance, and access programs tailored to multicultural Canadian communities
- Real‑world evidence (RWE) collection and health‑economic modeling to support health‑technology assessments and reimbursement negotiations
- Market‑access consulting covering pre‑launch planning, pricing guidance, HTA submissions, and payer engagement for innovative biopharmaceuticals
- Coordination of a national ecosystem linking patients, providers, non‑profits, and government agencies to streamline care pathways
- Support for ultra‑rare and gene‑therapy indications, including regulatory affairs and CMC expertise